Certificate of Analysis (COA) View the laboratory certificate for this product [ View COA ]

Noventra Pharma Tirzepatide 30 mg Self-Mix

R 1,450.00 R 1,440.00
Add to WishlistCompare

Noventra Pharma Tirzepatide 30 mg — Multidose Vial Kit

Dual-Receptor Research | Metabolic Health | Weight-Management Research

Product Overview

Noventra Pharma Tirzepatide 30 mg is a vial-format product labelled as containing a 30 mg multidose ampule, accompanied by a 2 ml ampule of bacteriostatic water.

Tirzepatide is a dual GIP and GLP-1 receptor agonist studied for its role in appetite regulation, blood-glucose control and body-weight management. Its activity across these two metabolic hormone pathways has made it an important focus of clinical research into obesity and type 2 diabetes.

Key Research Findings

Clinical trials have demonstrated several important effects of tirzepatide in studied patient populations:

  • Body-weight reduction: In the 72-week SURMOUNT-1 trial, average body-weight reductions ranged from 15.0% to 20.9% across the three tirzepatide groups in the primary analysis.

  • Appetite regulation: Tirzepatide influences metabolic signalling pathways involved in appetite and energy intake.

  • Blood-glucose control: Clinical research has demonstrated improvements in glycaemic control among people with type 2 diabetes.

  • Cardiometabolic markers: Trials reported improvements in waist circumference, blood pressure and several blood lipid measurements.

These findings reflect outcomes from controlled clinical trials using specified tirzepatide formulations and treatment protocols. They do not establish equivalent results for this particular product.

Key Features

Product: Tirzepatide 30 mg Self-Mix.

Stated total quantity: 30 mg. This is the total product quantity, not an individual dose.

Format: Self-mix. Product-specific preparation instructions should be confirmed with a qualified healthcare professional before use.

Dosage & Usage

Week 1: 1.5 mg

Week 2: 3.0 mg

Week 3: 4.5 mg

Week 4: 6.0 mg

Week 5 (Maintenance): 7.5 mg

Week 6: 9.0 mg

Week 7: 10.5 mg

Week 8 (Maximum): 12.0 mg

FAQ's & Tips

What is Tirzepatide 30 mg Self-Mix?

This product is listed as tirzepatide in a self-mix format, with a stated total quantity of 30 mg.

Does 30 mg mean one dose?

No. The stated total quantity should not be treated as an individual dose. A qualified healthcare professional should confirm the prescribed dose and instructions.

How do I prepare it?

Do not guess mixing quantities or use instructions from another product. Follow the product-specific instructions provided by the dispensing pharmacist or prescriber. If these are missing, ask for them before preparation.

How should I store it?

Follow the storage requirements on the product label, including any separate instructions that apply after mixing. Ask the dispensing pharmacist if anything is unclear.

What if the packaging is damaged or the label is unclear?

Do not use the product. Contact the supplier or dispensing pharmacist to resolve the issue first.

Can I change my dose myself?

Do not change your dose or dosing schedule without consulting your prescriber.

Research

Tirzepatide research references

The following publications provide background reading on clinical research involving tirzepatide. They are not preparation or dosing instructions.

Tirzepatide Once Weekly for the Treatment of Obesity — New England Journal of Medicine (2022)

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes — New England Journal of Medicine (2021)

Important: These references concern tirzepatide studied under clinical trial conditions. They do not establish the identity, purity, sterility, stability, safety or effectiveness of this specific 30 mg self-mix product, or its equivalence to the products used in the trials. Do not use these publications to determine mixing instructions or an individual dose.

Reviews